CN Patent

CN118338901A — 用于治疗癌症的cdk4抑制剂

Assigned to Pfizer Inc · Expires 2024-07-12 · 2y expired

What this patent protects

本公开提供治疗癌症的方法，其包括向需要其的个体给药治疗有效量的PF‑07220060。本公开还提供治疗癌症的方法，其包括向需要其的个体给药治疗有效量的PF‑07220060及内分泌治疗剂。

USPTO Abstract

本公开提供治疗癌症的方法，其包括向需要其的个体给药治疗有效量的PF‑07220060。本公开还提供治疗癌症的方法，其包括向需要其的个体给药治疗有效量的PF‑07220060及内分泌治疗剂。

Drugs covered by this patent

trametinib-dimethyl-sulfoxide (TRAMETINIB DIMETHYL SULFOXIDE)

Patent Metadata

Patent number: CN118338901A
Jurisdiction: CN
Classification: —
Expires: 2024-07-12
Drug substance claim: No
Drug product claim: No
Assignee: Pfizer Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.